DeutschNewstral
Article
bizjournals.com on 2018-02-16 23:48
East Bay cancer drug developer targets $100 million IPO
Related news
- East Bay cancer-fighting drug developer rocked by the death of two key executivesbizjournals.com
- Biotech giant snags East Bay cancer drug developer for potential $2.5 billionbizjournals.com
- East Bay cancer drug developer, jilted by Novartis, to cut 51 jobsbizjournals.com
- Waltham cancer drug developer Deciphera eyes $100M IPObizjournals.com
- East Bay medical device maker Penumbra tops targets with upsized $120M IPObizjournals.com
- After record IPO, East Bay company's CEO targets growth — and sleepbizjournals.com
- Another Bay Area life science company targets IPO, hopes to raise $115Mbizjournals.com
- East Bay biotech's different approach to cancer leads to $80 million IPObizjournals.com
- FDA rejects insulin pump from diabetes drug-delivery developer with key East Bay sitebizjournals.com
- 'Don't eat me' cancer drug developer asks investors to chow down on $115 million IPObizjournals.com
- Breast cancer drug developer Olema charts $100M IPO with help from former Genentech playersbizjournals.com
- Austin cancer drug developer takes $26M haircut on its IPO targetbizjournals.com
- How the latest Bay Area biotech IPO targets faster, better drug developmentbizjournals.com
Dementia drug developer Axovant's $315M IPOThe Salt Lake Tribune- Baltimore drug developer Cerecor plans $22.7M IPObizjournals.com
- Bluebird partners with Bay Area biotech on new cancer drug targetsbizjournals.com
- Cancer-fighting Peninsula biotech targets $100M IPObizjournals.com
- How an East Bay cancer fighter — once kicked to the curb by Big Pharma — picked up its 4th drug approvalbizjournals.com